Edwards Lifesciences (NYSE:EW) Shares Gap Up After Strong Earnings

Edwards Lifesciences Corporation (NYSE:EW) gapped up prior to trading on Friday following a stronger than expected earnings report. The stock had previously closed at $83.82, but opened at $88.00. Edwards Lifesciences shares last traded at $86.8420, with a volume of 1,411,581 shares changing hands.

The medical research company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.74 by $0.04. The company had revenue of $1.74 billion for the quarter, compared to analyst estimates of $1.70 billion. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 15.19%. Edwards Lifesciences’s revenue for the quarter was up 13.6% compared to the same quarter last year. During the same period in the previous year, the business earned $0.67 EPS. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS.

Key Edwards Lifesciences News

Here are the key news stories impacting Edwards Lifesciences this week:

• Positive Sentiment: Leerink Partners upgraded Edwards Lifesciences (EW) from market perform to outperform and set a $101 price target, implying meaningful upside from recent levels. Leerink Partners upgrade
• Positive Sentiment: The company reported strong Q2 results, with revenue up 13.6% year over year to $1.74 billion and adjusted EPS of $0.78, both ahead of Wall Street estimates. Q2 results press release
• Positive Sentiment: Management raised its full-year sales outlook to $6.6 billion-$6.9 billion and increased the low end of guidance, signaling confidence in continued demand for its heart-valve and transcatheter therapies. WSJ guidance update
• Positive Sentiment: Investors also responded favorably to strong sales momentum in the core TAVR franchise and improving expectations for TMTT, which helped push the stock up in extended trading after the earnings release. Reuters earnings article
• Neutral Sentiment: Analysts’ recent coverage remains constructive overall, with multiple firms maintaining or issuing positive targets around the $100-$110 range, reinforcing a favorable sentiment backdrop for the stock. Analyst targets overview

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on EW. Evercore reiterated an “outperform” rating and set a $100.00 target price on shares of Edwards Lifesciences in a research note on Monday, July 6th. Leerink Partners upgraded shares of Edwards Lifesciences from a “market perform” rating to an “outperform” rating and set a $101.00 target price for the company in a research report on Friday. Canaccord Genuity Group set a $85.00 target price on shares of Edwards Lifesciences and gave the stock a “hold” rating in a report on Friday, April 24th. Weiss Ratings reiterated a “hold (c)” rating on shares of Edwards Lifesciences in a research note on Friday, July 17th. Finally, Royal Bank Of Canada lifted their target price on shares of Edwards Lifesciences from $100.00 to $110.00 and gave the stock an “outperform” rating in a research report on Monday, July 13th. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and seven have assigned a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $99.09.

Insiders Place Their Bets

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 23,145 shares of the stock in a transaction that occurred on Wednesday, May 27th. The stock was sold at an average price of $86.42, for a total transaction of $2,000,190.90. Following the transaction, the vice president directly owned 98,611 shares in the company, valued at approximately $8,521,962.62. This represents a 19.01% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Andrew M. Dahl sold 568 shares of Edwards Lifesciences stock in a transaction on Friday, May 29th. The shares were sold at an average price of $86.08, for a total transaction of $48,893.44. Following the completion of the sale, the senior vice president owned 15,334 shares of the company’s stock, valued at $1,319,950.72. This represents a 3.57% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 45,577 shares of company stock worth $3,855,527. Corporate insiders own 0.31% of the company’s stock.

Hedge Funds Weigh In On Edwards Lifesciences

A number of institutional investors have recently modified their holdings of EW. Evermay Wealth Management LLC lifted its stake in Edwards Lifesciences by 4.0% in the fourth quarter. Evermay Wealth Management LLC now owns 3,304 shares of the medical research company’s stock valued at $282,000 after purchasing an additional 128 shares during the last quarter. Rehmann Capital Advisory Group increased its position in Edwards Lifesciences by 2.1% in the fourth quarter. Rehmann Capital Advisory Group now owns 6,399 shares of the medical research company’s stock worth $546,000 after buying an additional 130 shares during the last quarter. Florida Trust Wealth Management Co increased its position in Edwards Lifesciences by 1.5% in the fourth quarter. Florida Trust Wealth Management Co now owns 8,810 shares of the medical research company’s stock worth $751,000 after buying an additional 132 shares during the last quarter. McIlrath & Eck LLC raised its stake in shares of Edwards Lifesciences by 14.6% in the fourth quarter. McIlrath & Eck LLC now owns 1,057 shares of the medical research company’s stock valued at $90,000 after buying an additional 135 shares during the period. Finally, Quadrant Capital Group LLC raised its stake in shares of Edwards Lifesciences by 0.9% in the fourth quarter. Quadrant Capital Group LLC now owns 15,113 shares of the medical research company’s stock valued at $1,288,000 after buying an additional 136 shares during the period. 79.46% of the stock is owned by institutional investors and hedge funds.

Edwards Lifesciences Price Performance

The company has a current ratio of 4.42, a quick ratio of 3.63 and a debt-to-equity ratio of 0.06. The business has a 50-day moving average price of $87.70 and a 200 day moving average price of $83.89. The stock has a market cap of $49.96 billion, a PE ratio of 46.10, a PEG ratio of 2.12 and a beta of 0.86.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.